Canadian officials blast Trump's tariff threat and one calls Mexico comparison an insult
CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") CTOR , a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 , following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company; Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; key activities included: Manufactured initial inventory for launch and finalized supply chain agreements, Initiated recruitment of targeted field force with contract sales organization, Launched a marketing awareness campaign and engaged with all leading CTCL prescribers, Applied for a unique J-code within the Healthcare Common Procedure Coding System (HCPCS) to facilitate accurate reimbursement, Secured inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines, critical to clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S., and Initiated development of the patient support center to help patients access LYMPHIR expeditiously; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; and, Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab. The combination of these two immunomodulatory agents showed clinical benefit in relapsed or refractory gynecological neoplasms, resulting in: 27% objective response rate and 33% clinical benefit rate with median progression free survival of 57 weeks (range: 30-96 weeks), and A manageable safety profile whereby the regimen was well-tolerated with reversible treatment emergent adverse events and no definitive immune-related adverse events greater than or equal to grade 3 documented. Financial Highlights R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 ; G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $7.5 million for the full year ended September 30, 2024 , compared to $2.0 million for the full year ended September 30, 2023 ; and, Net loss was $21.1 million , or ($0.31) per share for the full year ended September 30, 2024 compared to a net loss of $12.7 million , or ($0.19) per share for the full year ended September 30, 2023 . "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $ - Capital Contribution of due to related party by parent $ 33,180,961 $ - Prepaid Manufacturing transferred to Inventory $ 6,134,895 $ - View original content to download multimedia: https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-full-year-2024-financial-results-and-provides-business-update-302339671.html SOURCE Citius Oncology, Inc. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Warren Buffett gives away another $1.1B and plans for distributing his $147B fortune after his death
VICTORIA — British Columbia Premier David Eby says 25-per-cent U.S. tariffs on Canadian goods would be "devastating" for the province's lumber and forestry industries. He made the comment ahead of a meeting with fellow first ministers and Prime Minister Justin Trudeau. Eby was scheduled to participate in the virtual meeting on Wednesday to discuss U.S. president-elect Donald Trump's threat to impose the tariffs unless Canada and Mexico stop illegal border crossings and prevent illicit drugs from entering the United States. Eby said the lumber and forestry sectors are already strained by a recent increase in duties amid the ongoing U.S.-Canada dispute over softwood lumber. He said after the first meeting of his new cabinet in Victoria that the tariffs are "unjustified," and they would hurt Americans as much as they would Canadians. The premier said B.C. is a source of natural gas, wood products, minerals and other products that U.S. businesses depend on, and the tariff would hinder jobs and opportunities in the province while making "life more expensive for Americans." Eby and Ottawa have called for a united front dealing with Trump's tariff plan, which he announced on social media on Monday. Eby said B.C. officials had repeatedly raised concerns with Ottawa over organized crime and illicit drugs, such as fentanyl, in relation to border security. "It's a priority for us. It has been for a while, we've written to Ottawa about it. Doesn't justify the tariffs, but it does mean that we can talk about those issues as well." Eby said Trump's proposed tariff "doesn't make economic sense," and the measure is not necessary to address issues at the border. The premier said he believes B.C. has a strong case to make for the tariff being "badly placed" if Trump's priority is to reduce costs for Americans. "I think the premiers are unified," Eby said. "There are 13 of us plus the prime minister. It's a big group of people with different political perspectives, but on this issue of ensuring that we're protecting the people in our country from these unjustified tariffs, I believe we're completely in line on that question." This report by The Canadian Press was first published Nov. 27, 2024. The Canadian PressFortune Brands Innovations Inc. stock falls Tuesday, underperforms marketIan Schieffelin, Clemson topple Penn State to win Sunshine Slam
In today’s newsletter, a deep dive into how the streaming service upended our listening habits, and then: The expansion of Los Alamos Susan B. Glasser reflects on the year in politics Revisiting Big Star’s “Radio City” Is There Any Escape from the Spotify Syndrome? The history of recorded music is now at our fingertips. But the streamer’s algorithmic skill at giving us what we like may keep us from what we’ll love. Spotify’s yearly “Wrapped” has become a defining project for the company, with its social-media-ready graphics that allow users to connect with listeners around the world and to reflect on their year. A new book from Liz Pelly, which Hua Hsu reviews for this week’s issue, offers a comprehensive look into how “Wrapped” and other features of the streaming service have changed not just how we listen to music but what we listen to. When Spotify learned, early on, to track user behavior, it began to anticipate our habits. As a result, “we’ve been conditioned to want hyper-personalization from our digital surroundings,” Hsu writes. “The collection of so much personalized data—around what time of day we turn to Sade or how many seconds of a NewJeans song we play—suggests a future without risk, one in which we will never be exposed to anything we may not want to hear.” Read the story » The Lede New Mexico’s Nuclear-Weapons Boom The laboratory at Los Alamos is growing at a pace not seen since J. Robert Oppenheimer and the Manhattan Project. “In recent years, Los Alamos has been essential to a sweeping 1.7-trillion-dollar update of the country’s nuclear arsenal, which comes as China expands its atomic-weapons program and Russia assumes a newly confrontational stance,” Abe Streep writes. Read the story » The Weird New Normal of Donald Trump in 2024 In Big Star’s “Radio City,” the Old Spells Don’t Work Daily Cartoon Link copied Play the holiday crossword. Today’s theme: 2024 in news and politics. P.S. Charles Darwin set sail on the H.M.S. Beagle today in 1831, kicking off the voyage that laid the foundation for his theory of evolution. Six years after he returned from his trip, he moved with his wife and two children to Down House, in rural Kent, England. It was there that he finished the first manuscript for “On the Origin of Species”—and had eight more children. Nine drawings by his children appear on the back of that manuscript, including an image of a green fish with pink legs and fins and a bright-blue umbrella . ☂️ Hannah Jocelyn contributed to this edition.Pierce's 20 lead Presbyterian past Youngstown State 67-42
The New York Rangers will play the second game of their three-game road trip versus the Tampa Bay Lightning Saturday night, but they likely did not travel in good spirits after a tough stretch before the Christmas break. Last season's Eastern Conference runners-up were humming along following a 4-3 win over the Vancouver Canucks on Nov. 19, climbing to a 12-4-1 record. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. As property values continue to outpace inflation, property taxes are taking a bigger bite out of homeowners’ wallets. A new analysis from Construction Coverage breaks down property tax rates by state, county, and city to reveal where homeowners have the greatest burden. Click for more. Where Are U.S. Property Taxes Highest and Lowest? A State, County, and City AnalysisTrump brings back government by social media
Bezos' Blue Origin gets FAA license for its first New Glenn rocket launchThe long sports-filled Thanksgiving weekend is a time when many Americans enjoy gathering with friends and family for good food, good company and hopefully not too much political conversation. Also on the menu — all the NFL and college sports you can handle. Here's a roadmap to one of the biggest sports weekends of the year, with a look at marquee games over the holiday and how to watch. All times are in EST. All odds are by BetMGM Sportsbook. What to watch Thursday • NFL: There is a triple-header lined up for pro football fans. Chicago at Detroit, 12:30 p.m., CBS: Rookie quarterback Caleb Williams and the Bears go against the Lions, who are one of the favorites to reach the Super Bowl in February. Lions favored by 10. New York at Dallas, 4:30 p.m., Fox: The Giants and Cowboys are both suffering through miserable seasons and are now using backup quarterbacks for different reasons. But if Dallas can figure out a way to win, it will still be on the fringe of the playoff race. Cowboys favored by 3 1/2. People are also reading... Miami at Green Bay, 8:20 p.m., NBC/Peacock: The Packers stumbled slightly out of the gate but have won six of their past seven games. They'll need a win against Miami to try to keep pace in the NFC North. Packers favored by 3. • College Football: Memphis at No. 18 Tulane, 7:30 p.m., ESPN. If college football is your jam, this is a good warmup for a big weekend. The Tigers try to ruin the Green Wave’s perfect record in the American Athletic Conference. Tulane is favored by 14. What to watch Friday • NFL: A rare Friday showdown features the league-leading Chiefs. Las Vegas at Kansas City, 3 p.m. Prime Video: The Chiefs and quarterback Patrick Mahomes are 12-point favorites over the Raiders. • College Basketball: Some of the top programs meet in holiday tournaments around the country. Battle 4 Atlantis championship, 5:30 p.m., ESPN: One of the premier early season tournaments, the eight-team field includes No. 3 Gonzaga, No. 14 Indiana and No. 24 Arizona. Rady Children's Invitational, 6 p.m., Fox: It's the championship game for a four-team field that includes No. 13 Purdue and No. 23 Mississippi. • College Football: There is a full slate of college games to dig into. Oregon State at No. 11 Boise State, noon, Fox: The Broncos try to stay in the College Football Playoff hunt when they host the Beavers. Boise State favored by 19 1/2. Oklahoma State at No. 23 Colorado, noon, ABC: The Buffaloes and Coach Prime are still in the hunt for the Big 12 championship game when they host the Cowboys. Colorado favored by 16 1/2. Georgia Tech at No. 6 Georgia, 7:30 p.m., ABC: The Bulldogs are on pace for a spot in the CFP but host what could be a tricky game against rival Georgia Tech. Georgia favored by 19 1/2. • NBA. After taking Thanksgiving off, pro basketball returns. Oklahoma City at Los Angeles Lakers, 10 p.m., ESPN: The Thunder look like one of the best teams in the NBA's Western Conference. They'll host Anthony Davis, LeBron James and the Lakers. Listen now and subscribe: Apple Podcasts | Google Podcasts | Spotify | RSS Feed | SoundStack | All Of Our Podcasts Los Angeles Lakers forward LeBron James dunks during the first half of a Nov. 23 game against the Denver Nuggets in Los Angeles. Mark J. Terrill, Associated Press What to watch Saturday • College Football. There are more matchups with playoff implications. Michigan at No. 2 Ohio State, noon, Fox: The Wolverines are struggling one season after winning the national title. They could make their fan base a whole lot happier with an upset of the Buckeyes. Ohio State favored by 21. No. 7 Tennessee at Vanderbilt, noon, ABC: The Volunteers are a fairly big favorite and have dominated this series, but the Commodores have been a tough team this season and already have achieved a monumental upset over Alabama. Tennessee favored by 11. No. 16 South Carolina at No. 12 Clemson, noon, ESPN: The Palmetto State rivals are both hanging on the edge of the CFP playoff race. A win — particularly for Clemson — would go a long way toward clinching its spot in the field. Clemson favored by 2 1/2. No. 3 Texas at No. 20 Texas A&M, 7:30 p.m. ABC: The Aggies host their in-state rival for the first time since 2011 after the Longhorns joined the SEC. Texas favored by 5 1/2. Washington at No. 1 Oregon, 7:30 p.m., NBC: The top-ranked Ducks have been one of the nation’s best teams all season. They’ll face the Huskies, who would love a marquee win in coach Jedd Fisch’s first season. Oregon favored by 19 1/2. • NBA: A star-studded clash is part of the league's lineup. Golden State at Phoenix, 9 p.m., NBA TV: Steph Curry and the Warriors are set to face the Suns' Big Three of Kevin Durant, Devin Booker and Bradley Beal. What to watch Sunday • NFL: It's Sunday, that says it all. Pittsburgh at Cincinnati, 1 p.m., CBS: Joe Burrow is having a great season for the Bengals, who are struggling in other areas. They need a win to stay in the playoff race, hosting a Steelers team that's 8-3 and won five of their past six. Bengals favored by 3. Arizona at Minnesota, 1 p.m., Fox: The Cardinals are tied for the top of the NFC West while the Vikings are 9-2 and have been one of the biggest surprises of the season with journeyman Sam Darnold under center. Vikings favored by 3 1/2. Philadelphia at Baltimore, 4:25 p.m., CBS: Two of the league's most electric players will be on the field when Saquon Barkley and the Eagles travel to face Lamar Jackson and the Ravens. Ravens favored by 3. San Francisco at Buffalo, 8:20 p.m. NBC/Peacock: The 49ers try to get back to .500 against the Bills, who have won six straight. Bills favored by 7. • NBA. The best teams in the Eastern Conference meet in a statement game. Boston at Cleveland, 6 p.m., NBA TV: The defending champion Celtics travel to face the Cavs, who won their first 15 games to start the season. • Premier League: English soccer fans have a marquee matchup. Manchester City at Liverpool, 11 a.m., USA Network/Telemundo. The two top teams meet with Manchester City trying to shake off recent struggles. • Auto Racing: The F1 season nears its conclusion. F1 Qatar Grand Prix, 11 a.m., ESPN2 – It's the penultimate race of the season. Max Verstappen already has clinched his fourth consecutive season championship. Who rules the sidelines? A look at the 10 winningest NFL coaches Who rules the sidelines? A look at the 10 winningest NFL coaches Before the 2023 National Football League season started, it seemed inevitable that Bill Belichick would end his career as the winningest head coach in league history.He had won six Super Bowls with the New England Patriots and 298 regular-season games, plus 31 playoff games, across his career. Then the 2023 season happened.Belichick's Patriots finished 4-13, the franchise's worst record since 1992. At the end of the year, Belichick and New England owner Robert Kraft agreed to part ways.And now, during the 2024 season, Belichick is on the sideline. He's 26 wins from the #1 spot, a mark he'd reach in little more than two seasons if he maintained his .647 career winning percentage.Will he ascend the summit? It's hard to tell. Belichick would be 73 if he graced the sidelines next season—meaning he'd need to coach until at least 75 to break the all-time mark. Only one other NFL coach has ever helmed a team at age 73: Romeo Crennel in 2020 for the Houston Texans.With Belichick's pursuit of history stalled, it's worth glancing at the legends who have reached the pinnacle of coaching success. Who else stands among the 10 winningest coaches in NFL history?Stacker ranked the coaches with the most all-time regular-season wins using data from Pro Football Reference. These coaches have combined for 36 league championships, which represents 31.6% of all championships won throughout the history of pro football. To learn who made the list, keep reading.You may also like: Ranking the biggest NFL Draft busts of the last 30 years Bettmann/Contributor // Getty Images #10. Dan Reeves - Seasons coached: 23- Years active: 1981-2003- Record: 190-165-2- Winning percentage: .535- Championships: 0Dan Reeves reached the Super Bowl four times—thrice with the Denver Broncos and once with the Atlanta Falcons—but never won the NFL's crown jewel. Still, he racked up nearly 200 wins across his 23-year career, including a stint in charge of the New York Giants, with whom he won Coach of the Year in 1993.In all his tenures, he quickly built contenders—the three clubs he coached were a combined 17-31 the year before Reeves joined and 28-20 in his first year. However, his career ended on a sour note as he was fired from a 3-10 Falcons team after Week 14 in 2003. Bettmann/Contributor // Getty Images #9. Chuck Noll - Seasons coached: 23- Years active: 1969-91- Record: 193-148-1- Winning percentage: .566- Championships: 4Chuck Noll's Pittsburgh Steelers were synonymous with success in the 1970s. Behind his defense, known as the Steel Curtain, and offensive stars, including Terry Bradshaw, Franco Harris, and Lynn Swann, Noll led the squad to four Super Bowl victories from 1974 to 1979. Noll's Steelers remain the lone team to win four Super Bowls in six years, though Andy Reid and Kansas City could equal that mark if they win the Lombardi Trophy this season.Noll was elected to the Pro Football Hall of Fame in 1993, two years after retiring. His legacy of coaching success has carried on in Pittsburgh—the club has had only two coaches (Bill Cowher and Mike Tomlin) since Noll retired. Focus on Sport // Getty Images #8. Marty Schottenheimer - Seasons coached: 21- Years active: 1984-98, 2001-06- Record: 200-126-1- Winning percentage: .613- Championships: 0As head coach of Cleveland, Kansas City, Washington, and San Diego, Marty Schottenheimer proved a successful leader during the regular season. Notably, he was named Coach of the Year after turning around his 4-12 Chargers team to a 12-4 record in 2004.His teams, however, struggled during the playoffs. Schottheimer went 5-13 in the postseason, and he never made it past the conference championship round. As such, the Pennsylvania-born skipper is the winningest NFL coach never to win a league championship. Focus on Sport // Getty Images #6. Curly Lambeau - Seasons coached: 33- Years active: 1921-53- Record: 226-132-22- Winning percentage: .631- Championships: 6An early stalwart of the NFL, Curly Lambeau spent 29 years helming the Green Bay Packers before wrapping up his coaching career with two-year stints with the Chicago Cardinals and Washington. His Packers won titles across three decades, including the league's first three-peat from 1929-31. Notably, he experienced only one losing season during his first 27 years with Green Bay, cementing his legacy of consistent success.Born in Green Bay, Lambeau co-founded the Packers and played halfback on the team from 1919-29. He was elected to the Hall of Fame as a coach and owner in 1963, two years before his death.You may also like: Countries with the most active NFL players Bettmann/Contributor // Getty Images #5. Tom Landry - Seasons coached: 29- Years active: 1960-88- Record: 250-162-6- Winning percentage: .607- Championships: 2The first head coach of the Dallas Cowboys, Tom Landry held the position for his entire 29-year tenure as an NFL coach. The Cowboys were especially dominant in the 1970s when they made five Super Bowls and won the big game twice. Landry was known for coaching strong all-around squads and a unit that earned the nickname the "Doomsday Defense."Between 1966 and 1985, Landry and his Cowboys enjoyed 20 straight seasons with a winning record. He was elected to the Hall of Fame in 1990. Focus on Sport // Getty Images #4. Andy Reid - Seasons coached: 26- Years active: 1999-present- Record: 267-145-1- Winning percentage: .648- Championships: 3The only active coach in the top 10, Andy Reid has posted successful runs with both the Philadelphia Eagles and Kansas City. After reaching the Super Bowl once in 14 years with the Eagles, Reid ratcheted things up with K.C., winning three titles since 2019.As back-to-back defending champions, Reid and Co. are looking this season to become the first franchise to three-peat in the Super Bowl era and the third to do so in NFL history after the Packers of 1929-31 and '65-67. Time will tell if Reid and his offensive wizardry can lead Kansas City to that feat. Jamie Squire // Getty Images #3. Bill Belichick - Seasons coached: 29- Years active: 1991-95, 2000-23- Record: 302-165- Winning percentage: .647- Championships: 6The most successful head coach of the 21st century, Bill Belichick first coached the Cleveland Browns before taking over the New England Patriots in 2000. With the Pats, Belichick combined with quarterback Tom Brady to win six Super Bowls in 18 years.Belichick and New England split after last season when the Patriots went 4-13—the worst record of Belichick's career. His name has swirled around potential coaching openings, but nothing has come of it. Belichick has remained in the media spotlight with his regular slot on the "Monday Night Football" ManningCast. Tom Pennington // Getty Images #1. Don Shula - Seasons coached: 33- Years active: 1963-95- Record: 328-156-6- Winning percentage: .677- Championships: 2The winningest head coach in NFL history is Don Shula, who first coached the Baltimore Colts (losing Super Bowl III to Joe Namath and the New York Jets) for seven years before leading the Miami Dolphins for 26 seasons. With the Fins, Shula won back-to-back Super Bowls in 1972 and 1973, a run that included a 17-0 season—the only perfect campaign in NFL history.He also coached quarterback great Dan Marino in the 1980s and '90s, but the pair made it to a Super Bowl just once. Shula was inducted into the Hall of Fame in 1997.Story editing by Mike Taylor. Copy editing by Robert Wickwire. Photo selection by Lacy Kerrick.You may also like: The 5 biggest upsets of the 2023-24 NFL regular season Bettmann/Contributor // Getty Images Be the first to know
Rigetti Computing (RGTI) continued to rise spectacularly on Friday, with shares seen increasing by more than 13% to $17.53 during morning trading. Advertisement The gain follows a record close at $15.44 on Thursday, marking the fifth consecutive session of gains for the quantum-computing services company. Advertisement Rigetti’s shares have skyrocketed more than 1,794% this year, a movement that has placed the company for its best annual performance on record. The surge is a significant comeback for a stock that, until mid-December, had remained below $1 for extended periods. Rigetti, which debuted on the Nasdaq in March 2022 after a SPAC merger, initially reached highs of $11.37 but struggled to regain those levels until this year’s rally. Now, as it continues its rally, the stock may hit another all-time high on Friday. Rigetti rises as part of a broader rally in quantum computing stocks Rigetti’s unprecedented rise reflects the broader rally being witnessed by quantum computing stocks, and investor enthusiasm for the sector. The share price of Quantum Computing (QUBT) climbed by 6.4% before losing the gains and slipping into the red, while D-Wave Quantum (QBTS) gained 2.53%. QUBT has gained more than 2,006% YTD. Quantum Corp. (QMCO) and Quantum-Si (QSI) surged by 6.2% and 68.9%, respectively. What’s driving market excitement for Rigetti is its ambitious technological roadmap. The company plans to deploy a 36-qubit system by mid-2025, using its proprietary superconducting qubit technology, which offers gate speeds of 60 to 80 nanoseconds—far outpacing competitors. A larger, 100-plus-qubit system is also planned for later in 2025. Analyst forecasts for the quantum computing market Rigetti’s Q3 revenue remained modest at $2.4 million, but the company’s $92.6 million cash position provides a solid foundation for executing its vision. Analysts see quantum computing as a transformative technology with vast potential, supported by McKinsey’s forecast that the market could reach $45 billion to $131 billion by 2040. With its recent achievements and ambitious plans, Rigetti is emerging as a leader in a rapidly expanding field, signalling a bright future for quantum computing innovation. Former Rigetti executive sells into its strength Rigetti’s strong rally prompted at least one investor to sell into its strength. Former General Counsel of Rigetti, Richard Danis sold 624,262 shares in December, earning $4.7 million, according to filings with the Securities and Exchange Commission. His transactions included a sale of 233,423 shares on Monday, Dec. 23, for $2.6 million at an average price of $11.03 per share. Danis had also indicated plans to sell an additional 250,000 shares at $11 per share, a transaction that would net $2.8 million. Danis resigned from his role on Nov. 30, and Rigetti that his post-resignation consulting agreement was terminated by mutual agreement earlier this month. Should you sell too? , financial analyst at Invezz, there are compelling reasons to sell quantum stocks like RGTI, QSI, and others. He says, The first major reason to sell quantum computing stocks like Rigetti Computing, Quantum Corporation, and IONQ is that major themes often don’t work out in the long term. This performance is mostly because the market is usually driven by fear and greed. Nyaga has compared the current sentiment to the initial surge seen in cannabis and electric vehicle stocks which plunged after seeing a hype. Secondly, according to Nyaga, the Wyckoff method shows that stocks will crash due to a concept called mean reversion. “This situation is where stocks and other assets drop and return to their mean levels after a strong surge. This means the reversion concept has recently worked well in the crypto industry.” Additionally, their stocks have become highly overbought as their Relative Strength Index (RSI) and Stochastic Oscillators have soared, he says, adding stocks often retreat when they become highly overbought. Lastly, he says, quantum computing stocks will crash because their valuation metrics have become highly stretched in the past few months.
13 British healthcare companies take part in 10th UK-India Healthcare Trade MissionPet owner's urgent warning for anyone sleeping with their pet: 'It saved my eye'None
CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 , following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company; Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; key activities included: Manufactured initial inventory for launch and finalized supply chain agreements, Initiated recruitment of targeted field force with contract sales organization, Launched a marketing awareness campaign and engaged with all leading CTCL prescribers, Applied for a unique J-code within the Healthcare Common Procedure Coding System (HCPCS) to facilitate accurate reimbursement, Secured inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines, critical to clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S., and Initiated development of the patient support center to help patients access LYMPHIR expeditiously; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; and, Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab. The combination of these two immunomodulatory agents showed clinical benefit in relapsed or refractory gynecological neoplasms, resulting in: 27% objective response rate and 33% clinical benefit rate with median progression free survival of 57 weeks (range: 30-96 weeks), and A manageable safety profile whereby the regimen was well-tolerated with reversible treatment emergent adverse events and no definitive immune-related adverse events greater than or equal to grade 3 documented. Financial Highlights R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 ; G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $7.5 million for the full year ended September 30, 2024 , compared to $2.0 million for the full year ended September 30, 2023 ; and, Net loss was $21.1 million , or ($0.31) per share for the full year ended September 30, 2024 compared to a net loss of $12.7 million , or ($0.19) per share for the full year ended September 30, 2023 . "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $Mama Meals Provides Over $7,400 Worth of Postpartum Meals to New Moms in North Carolina